GENVEC, INC.
Adenoviral vector-based gene therapy for hemophilia using pulmonary endothelial targeting and CRISPR/Cas9 integration
Follows are private to you and power your alerts
Updated · aigenvec.cloudflareaccess.com
- Sector
- Biotech
- Headquarters
- Gaithersburg, MD
- Latest Form D
- $2M, Jan 2010
- Total capital
- $27.5M
- Federal grants
- $215K
- 1 award · 2017
- Rank in peer group#351 of 392
- Private capital raised
- $2M
- 1 Form D · last Jan 2010
- 201 months since last filing
- Federal contracts
- $25.3M
- 7 awards · Defense, Health and Human S, Homeland Security
- Rank in Biotech#33 of 4373
- Granted patents
- 26
- 14 pending · first 2016
- Rank in peer group#5 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · In Vivo Editing for Hemophilia Gene Therapy$215K
- Federal contractDefense · Malaria Manufacture Of 3 Ad Vectors$1.4M
- Federal contractDefense · Program For Stability Testing For$141K
- Private capital raisedForm D · SEC · 1st filing$2M
- Federal contractHomeland Security · The Purpose Of This Cost Plus Fixed Fee Contract, Which Is Awarded Under The Department Of Homeland Security (dhs) Long Range Broad Agency Announcement, Is To Provide Support For Research And Development Of A Molecular Foot-and-mouth Disease (fmd) Vaccine, In Accordance With The Attached Terms And Conditions And Statement Of Work.$5.7M
- Federal contractDefense · Malaria Research Program Proteins$247K
- Federal contractHealth and Human S · Technology Licensing Cell Development And Manufacturing Technical Support$16.1M
Show 1 earlier federal award
- Federal contractDefense$1.7M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Federal first
61months
from GENVEC, INC.’s first federal award to its first private round.
- First federal award · Jan 2005
- Defense · $1.7M
- First Form D · Jan 2010
- $2M · 1st Form D
- Awards before first raise
- 4 awards
An association in public records, not a cause or a prediction.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#5 · top 1%
- Linked publications#13 · top 3%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Douglas J. SwirskyExecutive OfficerNamed in SEC Form D filings
- Joshua M. RuchDirectorNamed in SEC Form D filings
- Kevin M. RooneyDirectorNamed in SEC Form D filings
- Marc M. SchneebaumDirectorNamed in SEC Form D filings
- Paul H. FischerDirector, Executive OfficerNamed in SEC Form D filings
- Wayne T. HockmeyerDirectorNamed in SEC Form D filings
Show all 8 people
- William N. KelleyDirectorNamed in SEC Form D filings
- Zola P. HorovitzDirectorNamed in SEC Form D filings
What it has protected
USPTO · 26 granted of 40- GrantedSimian (gorilla) Adenovirus Or Adenoviral Vectors And Methods Of UseUSPTOUS 11,359,214
- GrantedAdenoviral Vector Encoding Human Atonal HOMOLOG-1 (HATH1)USPTOUS 11,279,951
- GrantedAdenovectors For Delivery Of Therapeutic Genetic Material Into T CellsUSPTOUS 11,155,832
Show all 40 patent records
- Simian (gorilla) Adenovirus Or Adenoviral Vectors And Methods Of UseJun 14, 2022 · US 11,359,214Granted
- Adenoviral Vector Encoding Human Atonal HOMOLOG-1 (HATH1)Mar 22, 2022 · US 11,279,951Granted
- Adenovectors For Delivery Of Therapeutic Genetic Material Into T CellsOct 26, 2021 · US 11,155,832Granted
- Adenovectors For Delivery Of Therapeutic Genetic Material Into T CellsSep 30, 2021 · Application 17229098Pending
- Modified Serotype 28 Adenoviral VectorsSep 2, 2021 · Application 17200012Pending
- Affenadenovirus (gorilla) Or Adenoviral Vectors And Methods Of UseJun 15, 2021 · US 11,034,975Granted
- Modified Serotype 28 Adenoviral VectorsMar 16, 2021 · US 10,947,560Granted
- Affenadenovirus (gorilla) Or Adenoviral Vectors And Methods Of UseOct 6, 2020 · US 10,792,376Granted
- Simian (gorilla) Adenovirus Or Adenoviral Vectors And Methods Of UseSep 29, 2020 · US 10,787,682Granted
- Malaria Antigens And Methods Of UseSep 22, 2020 · US 10,780,153Granted
- Method For Propagating Adenoviral Vectors Encoding Inhibitory Gene ProductsMay 5, 2020 · US 10,640,776Granted
- Malaria Antigens And Methods Of UseJun 11, 2019 · US 10,314,901Granted
- Affenadenovirus (gorilla) Or Adenoviral Vectors And Methods Of UseApr 30, 2019 · US 10,272,162Granted
- Affenadenovirus (gorilla) Or Adenoviral Vectors And Methods Of UseApr 16, 2019 · US 10,260,074Granted
- Herpes Simplex Virus VaccineApr 4, 2019 · Application 16156520Pending
- Herpes Simplex Virus VaccineNov 13, 2018 · US 10,125,174Granted
- Simian (gorilla) Adenovirus Or Adenoviral Vectors And Methods Of UseAug 28, 2018 · US 10,059,962Granted
- Malaria Antigens And Methods Of UseJul 17, 2018 · US 10,022,432Granted
- Adenoviral Vector Encoding Human Atonal HOMOLOG-1 (HATH1)Apr 24, 2018 · US 9,951,351Granted
- Malaria Antigens And Methods Of UseDec 5, 2017 · US 9,833,502Granted
- Modified Serotype 28 Adenoviral VectorsOct 17, 2017 · US 9,790,519Granted
- Affenadenovirus (gorilla) Or Adenoviral Vectors And Methods Of UseAug 8, 2017 · US 9,725,738Granted
- Herpes Simplex Virus VaccineJun 13, 2017 · US 9,676,824Granted
- Affenadenovirus (gorilla) Or Adenoviral Vectors And Methods Of UseApr 25, 2017 · US 9,629,906Granted
- Simian (gorilla) Adenovirus Or Adenoviral Vectors And Methods Of UseApr 11, 2017 · US 9,617,560Granted
- Methods Of Propagating Monkey Adenoviral VectorsMar 7, 2017 · US 9,586,998Granted
- Adenoviral Vector-based Respiratory Syncytial Virus (rsv) VaccineFeb 28, 2017 · US 9,580,476Granted
- Method For Propagating Adenoviral Vectors Encoding Inhibitory Gene ProductsOct 20, 2016 · Application 15193280Pending
- Method For Propagating Adenoviral Vectors Encoding Inhibitory Gene ProductsJul 12, 2016 · US 9,388,429Granted
- Affenadenovirus (gorilla) Or Adenoviral Vectors And Methods Of UseJan 12, 2016 · US 9,233,153Granted
- Adenoviral Vector-based Malaria VaccineJun 11, 2015 · Application 14373574Pending
- Methods Of Gene Therapy For Treating Disorders Of The Ear By Administering A Vector Encoding An Atonal-associated FactorJan 2, 2014 · Application 14024749Pending
- Muscle Cells And Their Use In Cardiac RepairApplication PCTUS2003008518Pending
- Composition And Method For Maintaining Non-enveloped Viral VectorsApplication PCTUS2003000831Pending
- Angiopoietin Related FactorsApplication PCTUS2002037660Pending
- Gene Transfer Vector CompositionApplication PCTUS2002035113Pending
- Therapeutic Regimen For Treating CancerApplication PCTUS2002035042Pending
- Viral Vector Production M Ethods And CompositionsApplication PCTUS2002035049Pending
- Adenoviral Vector And Related System And Methods Of Making And UseApplication PCTUS2002029111Pending
- Cells And Methods For Propagating Adenoviral VectorsApplication PCTUS2002024051Pending
Recent research by its founders
- Zopapogene imadenovec-drba, a novel non-replicating adenoviral vector-based immunotherapy: Effects on complete and durable responses in recurrent respiratory papillomatosis pivotal trial.20261 cites
- PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial202523 cites
- PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer202510 cites
Related companies, and why
- HAWAII BIOTECH, INC.Similar federal contract value in Biotech · $27.6M in contracts
- SYNEDGEN, INC.Similar federal contract value in Biotech · $26.6M in contracts
- 10X Genomics, Inc.Similar federal contract value in Biotech · $26.4M in contracts
- SANARIA INC.Similar federal contract value in Biotech · $25M in contracts
- Myriad GeneticsSimilar federal contract value in Biotech · $25M in contracts
- PARABON NANOLABS, INC.Similar federal contract value in Biotech · $24.7M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .